CHAPTER 05 // COLOPHON
What this zine is, and what it is not.
The colophon page. Editorial standards, sourcing methodology, and the line between editorial framing and clinical services.
What this is
CJC-1295 / GET is a hand-typed zine that reads the peer-reviewed research literature on CJC-1295 — a 30-amino-acid synthetic analog of growth hormone-releasing hormone. It takes the form of a 1990s-style photocopied reading-room zine because that visual register is honest about the subject: a regulatory grey-zone compound circulating through informal channels deserves a tone that admits the grey zone rather than papering over it with institutional sheen.
Every quantitative claim on the site cites a published source. The full bibliography is at /references. The zine is tied to no peptide vendor, compounding pharmacy, clinic, manufacturer, distributor, or research-chemical supplier, and nothing on it is medical advice.
What this is not
CJC-1295 / GET is not a clinic. There are no clinicians on staff because there is no staff in any clinical sense. There is no founder named Dr. Anyone. There is no physical address, no phone consultation, no telemedicine intake, no compounding partnership, no protocol generation, no patient onboarding, no prescription service. The editorial framing of the domain name — GET — refers to the practical research questions readers arrive with (where does this peptide come from, what physical forms exist, what does a Certificate of Analysis actually prove). It is not a claim that this site arranges acquisition of the substance for anyone.
The word doctor in the sibling domain cjc1295doctor.com is similarly editorial. Both domains are publishers of literature summaries, not service providers. Readers seeking medical advice about any health condition should consult a licensed clinician in person. Readers subject to WADA testing should consult their sport's anti-doping authority before considering any substance on the prohibited list.
How the editorial work is done
The pipeline is straightforward. A research pass pulls primary literature from PubMed, journal sites, ClinicalTrials.gov, FDA Pharmacy Compounding Advisory Committee briefing documents, and the World Anti-Doping Agency's published Prohibited List. A writing pass converts the findings into a small number of long-form summaries with inline [N] citations linked to the bibliography. Every dose number, every half-life, every percentage, every trial enrollment count, every study termination event, every regulatory action is tied to a specific named source.
Where the literature is sparse, the page says the literature is sparse. The published human evidence base for CJC-1295 is one complete Phase 1 PK study, one terminated Phase 2 trial without published efficacy data, and a small set of detection-methods papers. Pretending it is larger would be dishonest. The zine register is the visual acknowledgment that the editorial confidence here is calibrated to what the published record actually supports.
Disclaimer (read it twice)
CJC-1295 is not approved by the U.S. Food and Drug Administration for any human indication. ConjuChem's Phase 2 clinical development program was terminated in 2006. The FDA's December 4, 2024 Pharmacy Compounding Advisory Committee voted against including the reviewed CJC-1295 forms on the Section 503A Bulks List; FDA's page current as of April 22, 2026 records the withdrawn nomination outside Category 2, with the safety warnings still beside it. CJC-1295 is prohibited at all times under Section S2 of the 2025 World Anti-Doping Agency Prohibited List.
None of the content on this site is medical advice. No content here recommends any dose, route, schedule, source, or combination for any human use. The dose numbers cited on /dosage are reported because published studies used them, not because they are recommended. The zine reads the peer-reviewed record and stops there — not a clinic, not a vendor, not a prescription service.